摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-乙酰基-1,3-二氢-2H-苯并咪唑-2-酮 | 14394-91-3

中文名称
1-乙酰基-1,3-二氢-2H-苯并咪唑-2-酮
中文别名
1-(2-羟基-1H-苯并[D]咪唑基-1-基)乙酮;1-乙酰基-1H-苯并咪唑-2-醇
英文名称
1-acetyl-benzimidazol-2-(3H)-one
英文别名
1-Acetyl-2(3H)-benzimidazolinon;N-Acetyl-benzimidazolon;1-Acetyl-2-oxo-benzimidazolin;1-acetyl-1H-benzimidazol-2-ol;3-acetyl-1H-benzimidazol-2-one
1-乙酰基-1,3-二氢-2H-苯并咪唑-2-酮化学式
CAS
14394-91-3
化学式
C9H8N2O2
mdl
MFCD00276690
分子量
176.175
InChiKey
PAEZCOSIWFZPEG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.111
  • 拓扑面积:
    49.4
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933990090

SDS

SDS:297f6234dbb26e0683c393c2a7f76f44
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Live-Cell Protein Modification by Boronate-Assisted Hydroxamic Acid Catalysis
    作者:Christopher Adamson、Hidetoshi Kajino、Shigehiro A. Kawashima、Kenzo Yamatsugu、Motomu Kanai
    DOI:10.1021/jacs.1c07060
    日期:2021.9.22
    Selective methods for introducing protein post-translational modifications (PTMs) within living cells have proven valuable for interrogating their biological function. In contrast to enzymatic methods, abiotic catalysis should offer access to diverse and new-to-nature PTMs. Herein, we report the boronate-assisted hydroxamic acid (BAHA) catalyst system, which comprises a protein ligand, a hydroxamic
    在活细胞中引入蛋白质翻译后修饰 (PTM) 的选择性方法已被证明对研究其生物学功能很有价值。与酶法相比,非生物催化应该提供对各种新自然 PTM 的访问。在此,我们报道了硼酸盐辅助的异羟肟酸(BAHA)催化剂体系,该体系由蛋白质配体、异羟肟酸路易斯碱和二醇部分组成。与带有硼酸的酰基供体配合,我们的催化剂利用局部摩尔浓度效应来促进酰基转移到目标赖氨酸残基。我们的催化剂系统采用微摩尔浓度的试剂,并提供最小的脱靶蛋白反应性。至关重要的是,BAHA 对谷胱甘肽具有抗性,谷胱甘肽是一种阻碍活细胞内非生物化学的许多努力的代谢物。在人体细胞中表达的大肠杆菌二氢叶酸还原酶。我们的结果进一步确立了众所周知的硼酸-二醇络合作为真正的生物正交反应,在化学生物学和细胞内催化中的应用。
  • Inhibitors of the Salicylate Synthase (MbtI) from Mycobacterium tuberculosis Discovered by High-Throughput Screening
    作者:Mahalakshmi Vasan、João Neres、Jessica Williams、Daniel J. Wilson、Aaron M. Teitelbaum、Rory P. Remmel、Courtney C. Aldrich
    DOI:10.1002/cmdc.201000275
    日期:2010.12.3
    A simple steady‐state kinetic high‐throughput assay was developed for the salicylate synthase MbtI from Mycobacterium tuberculosis, which catalyzes the first committed step of mycobactin biosynthesis. The mycobactins are small‐molecule iron chelators produced by M. tuberculosis, and their biosynthesis has been identified as a promising target for the development of new antitubercular agents. The assay
    为来自结核分枝杆菌的水杨酸合酶 MbtI 开发了一种简单的稳态动力学高通量测定,该酶催化分枝杆菌素生物合成的第一个关键步骤。分枝杆菌素是由结核分枝杆菌产生的小分子铁螯合剂,并且它们的生物合成已被确定为开发新型抗结核药物的有希望的目标。该测定被小型化为 384 孔板格式,并在生物防御和新兴传染病卓越区域中心 (NSRB) 的国家筛选实验室进行了高通量筛选。确定了三类化合物,包括苯并异噻唑酮(I 类)、二芳基砜(II 类)和苯并咪唑-2-硫酮(III 类)。这些化合物系列中的每一个都被进一步研究以研究它们的生化机制和构效关系。苯并咪唑-2-硫酮4由于其有效的可逆抑制而成为最有前途的抑制剂。
  • Selenium‐Catalyzed Carbonylative Synthesis of 2‐Benzimidazolones from 2‐Nitroanilines with TFBen as the CO Source
    作者:Xinxin Qi、Rong Zhou、Jin‐Bao Peng、Jun Ying、Xiao‐Feng Wu
    DOI:10.1002/ejoc.201801739
    日期:2019.9
    A selenium‐catalyzed carbonylative reaction for the synthesis of 2‐benzimidazolones from 2‐nitroanilines has been developed. In this strategy, to avoid the usage of toxic CO gas, TFBen (benzene‐1,3,5‐triyl triformate) was used as a solid and stable CO precursor, and a variety of desired 2‐benzimidazolones were produced in moderate to excellent yields.
    已开发了一种硒催化的羰基化反应,用于从2-硝基苯胺合成2-苯并咪唑酮。在此策略中,为避免使用有毒的CO气体,TFBen(苯-1,3,5-三甲酸酯三甲酸酯)被用作固体和稳定的CO前体,并且生产了各种所需的2-苯并咪唑酮,其中中等至极好。产量。
  • Unexpected synthesis of novel 2-pyrone derivatives: crystal structures, Hirshfeld surface analysis and computational studies
    作者:Jihad Sebhaoui、Youness El Bakri、Chin-Hung Lai、Subramani Karthikeyan、El Hassane Anouar、Joel T. Mague、El Mokhtar Essassi
    DOI:10.1080/07391102.2020.1780943
    日期:2021.9.2
    arising in crystal packing are rationalized by means of the Hirshfeld surface analysis method. The major intermolecular contacts in the Hirshfeld surfaces of I–III are from H…H contacts. In addition, binding modes of I–III within Tyrosine-protein kinase JAK2 were investigated using molecular docking and molecular dynamics simulation studies. Communicated by Ramaswamy H. Sarma
    摘要 在这里,我们报告了三种新化合物的合成,即 1-acetyl-1H-benzimidazolo-2(3H)-one ( I ), N- (5-acetyl-6-methyl-2-oxo-2H-pyran-4-yl )- N- (2-乙酰氨基苯基)乙酰胺( II )和N- (2-乙酰氨基苯基) -N -2-氧代-2H-吡喃-4-基)乙酰胺( III )已合成并表征为单晶X-射线衍射。化合物I和II 分别在单斜空间群 P21/n 和 P21/c 中结晶,而化合物III在三斜空间群 P-1 中结晶。I - III的理论参数已通过密度泛函理论 (DFT) 使用混合泛函 B3LYP 和基组 6-311++G** 进行计算。将这些理论参数与通过 XRD 获得的实验参数进行了比较。晶体堆积中出现的显着分子间相互作用通过 Hirshfeld 表面分析方法进行了合理化。I – III的 Hirshfeld
  • Acinetobacter baumannii OxPhos inhibitors as selective anti-infective agents
    作者:Harvey Rubin、Trevor Selwood、Takahiro Yano、Damian G. Weaver、H. Marie Loughran、Michael J. Costanzo、Richard W. Scott、Jay E. Wrobel、Katie B. Freeman、Allen B. Reitz
    DOI:10.1016/j.bmcl.2014.11.020
    日期:2015.1
    The Gram-negative bacterium Acinetobacter baumannii is an opportunistic pathogen in humans and infections are poorly treated by current therapy. Recent emergence of multi-drug resistant strains and the lack of new antibiotics demand an immediate action for development of new anti-Acinetobacter agents. To this end, oxidative phosphorylation (OxPhos) was identified as a novel target for drug discovery research. Consequently, a library of similar to 10,000 compounds was screened using a membrane-based ATP synthesis assay. One hit identified was the 2-iminobenzimidazole 1 that inhibited the OxPhos of A. baumannii with a modestly high selectivity against mitochondrial OxPhos, and displayed an MIC of 25 mu M (17 mu g/mL) against the pathogen. The 2-iminobenzimidazole 1 was found to inhibit the type 1 NADH-quinone oxidoreductase (NDH-1) of A. baumannii OxPhos by a biochemical approach. Among various derivatives that were synthesized to date, des-hydroxy analog 5 is among the most active with a relatively tight SAR requirement for the N'-aminoalkyl side chain. Analog 5 also showed less cytotoxicity against NIH3T3 and HepG2 mammalian cell lines, demonstrating the potential for this series of compounds as anti-Acinetobacter agents. Additional SAR development and target validation is underway. (C) 2014 Elsevier Ltd. All rights reserved.
查看更多